$NWBO: TRY ... to suck up the beatings!
The 30-45 days “pickle”
“The Company anticipates submitting the MAA in approximately the next 30-45 days”.
I asked BARD
I asked ChatGBT
So, I guess its safe to say, that today, Friday 13th. 2023 is the latest day in the period for submitting MAA application to MHRA in the UK.
According to NWBOs latest PR from August 29th.
If one forgets, that NWBO also wrote “approximately” … that is.
And if one ALSO forgets, that NWBO never actually wrote, they would PR the submission.
With that in mind, we – the retailers - are sadly yet again put into another fine mess.
- Short and distort scammers take advantage of the situation on social medias to sow fear, uncertainty and doubt. The usual non invested posters on Investorshub. And its relatively easy for Market Makers to spoof and traverse the share price down on low volume.
- Speculations among retailers, which have now left many desolated and where some have now started to “fold” or sell out of their shares, which again plays right into Market Makers wish, to be able to cover at lower share prices.
Personally I was never a proponent for the company to come with information to guide and inform retailers, if they did not have something substantial to PR, that would REALLY make the stock come out of its long hibernation. With history in mind, it was my belief, that Market Markers would manage to sink separate PR’s about progress anyway. So why not just keep accumulating to the PR pile?
I must admit though, that the PR actually DID move the share price 125% on very low volume, a sign that Market Makers are not as strong as I had believed and that their ship will eventually sink, when NWBO finally decides to unleash hell.
But currently we find us to be in a “little bit of a pickle”, because not only are some retailers having doubts, some are also selling. Some folding. I see very hardcore long term retailers leave private groups on social media in despair, not ONLY because they are letting tinfoil hat fud get to them, but because they feel management is abandoning them.
If one say A, then they must say B.
If the company opts to PR they will submit in the next 30-45 days, then no matter they wrote “approximately” and left out they might not PR that, then that sets the play field, which fudders will adhere to and try to use to their advantage.
That’s what goes on right now on Investorshub, X (Twitter) and at other SoMe’s.
If one opts to guide retailers with a PR – not about submitting, but about GOING to submit – then that sets the stage for continuing support to retailers.
If the company PR’s today, then everything is fine and dandy.
If they are not able to, PR the submission will happen next week and outline the “why”. That will put a cork into fudders narratives and stop the bleeding nonsense polluting everything.
The “look ma …. Its Superman” fud!
We all know the feeling, when we come upon an article about a competing glioblastoma treatment, that PR’s progress. The fudders try to use that, by constantly linking to any article with any possible - or even impossible treatment or drug that is targeting glioblastoma.
Hell, DCVax-L has been a vaccine in progress since the end 90’s. We are two decades into its development. P3 trial started 2006. Enrollment stopped in 2015. A combo trial with poly-iclc started in 2010, which is nearing its ending. Linda Liau and the UCLA team have so much data at their disposal for not only how DCVax-L is optimized, but how they get it to be most efficient.
Fudders are trying to carpet bomb retailers with info about dendritic cell alternatives SurVax-M, AV-GBM-1, Celliponts DOC201.
Let’s use AI to ask some questions about these alternatives.
Ok, let's test those alternatives with some facts about DCVax-L.
How about the fact that DCVax-L will have orphan drug status?
How about asking if any of the alternatives, have in ANY WAY been tested in combo with checkpoint inhibitors or POLY-ICLC?
Just stop it will you? We can not put a cork into all these attempts to sow FUD, but we can at least agree upon, that no one is within years of getting to where NWBO is now.
And if you are still in doubt, let me refresh your memory.
Even though it shouldn’t be necessary to state, that WHAT HAVE been accomplished during the milestones reached, have been nothing less of extraordinary.
It shouldn’t NEITHER be necessary to state, that NONE of “our” competitors have been put through “the ringer” of financial markets crimes by a magnitude, like those NWBO have been recipient of.
Is it REALLY necessary to list, what our competitors have yet to reach, what NWBO did BESIDE running a trial?
- Data Lock
- Top Line Data presented
- Results peer-reviewed by 73 doctors
- Build UKs most certified cell and gene CDMO, MIA certified to manufacture SPECIFICALLY DCVax-L
- Advent Bio reached almost 100 people ready to start manufacturing
- Bought and developed Flaskworks making them able to scale and automate manufactoring
- PIP plan approved by MHRA with same trial design as original P3 trial
- A decade of compassionate use in the UK
- 165 global patents
- Combo trial with POLY-ICLC run at UCLA since 2010
- Results of said trial to be published in Nature
- Combo trial (SPORE 1) with Keytruda run at UCLA since 2019
- Linda Liau joins NWBOs SAB board
- Robert Prins in charge of researching efficacy with DCvax-L and checkpoint inhibitors for a decade at UCLA
- NWBO charges 7 Market Makers for many years of spoofing, having Cohen and Milstein take the case on contingence and their star lawyer Laura Posner to helm the case.
And if you in ANY way are doubting about MHRA being "on NWBOs" side, then you just have to remember this little collage of stuff thats been happening at the MHRA just this year, with the cherry on top being british politicians having URGED and RECOMMENDED MHRA and NICE to approve AND reimburse DCvax-L as quickly as possible.
It has NEVER been more important to state clear and unequivocally.
HOLD.